Mouse endurance and metabolic studies
- Reported quantity
- 30 mg/kg intraperitoneally
- Frequency
- Twice daily
- Study duration
- 10–28 days
30 mg/kg twice daily is the figure repeated across the original publications.
Protocols · Metabolic
SLU-PP-332: literature-reported ranges
SLU-PP-332 is a small-molecule ERR agonist described as an 'exercise mimetic' in press coverage. The entire published record is mouse work from a small number of laboratories, and no human data exists.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Compound at a glance
- Class
- Pan-ERR (estrogen-related receptor) agonist, small molecule
- Reported half-life
- Short in rodents; frequent administration is used in every published design
- Routes used in the literature
- Intraperitoneal in the published mouse work
- Also written as
- —
What the published studies reported
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
In-vitro ERR activation
- Reported quantity
- EC50 in the low nanomolar range across ERRα, β and γ
- Frequency
- Single exposure
- Study duration
- 24–48 hours
Pan-agonism across all three ERR subtypes is the pharmacological signature.
Dosage chart
These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.
SLU-PP-332 · 5 mg Vial
SLU-PP-332 is dosed at 1.25 mg–2.5 mg daily via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 1.67 mg/mL. This information is for research and educational use only.
- Evidence Base
- Preclinical only—in vivo mouse studies with intraperitoneal dosing (25–50 mg/kg twice daily).
- Reconstitute
- Add 3.0 mL bacteriostatic water → ~ 1.67 mg/mL concentration.
- Murine dose range
- 1250–2500 mcg daily (for a 25 g mouse), administered in two divided doses.
- Easy measuring
- At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.
- Storage
- Lyophilized: −20 °C (−4 °F); reconstituted: 2–8 °C (35.6–46.4 °F).
Murine-Equivalent Protocol (3 mL = ~1.67 mg/mL)
| Phase | Daily Dose (mcg) | Per-Injection Dose (mcg) | Units per Injection (mL) |
|---|---|---|---|
| Weeks 1–2 | 1250 mcg | 625 mcg | 37.5 units (0.375 mL) |
| Weeks 3–8 | 2500 mcg | 1250 mcg | 75 units (0.75 mL) |
Mixed with 3 ml of bacteriostatic water
The same arithmetic for every vial size SLU-PP-332 is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.
SLU-PP-332 · 3 ml bacteriostatic water
| Vial size | Concentration | Per 1 unit |
|---|---|---|
| 5 mg | 1.67 mg/ml | 17 mcg |
| 10 mg | 3.33 mg/ml | 33 mcg |
No single reported amount applies to this compound, so only the concentration and the value of one unit are shown. Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.
Reconstitution maths
Not a peptide — supplied as a powder requiring an organic co-solvent such as DMSO before dilution. It does not dissolve in bacteriostatic water.
Open the reconstitution calculatorHow to read these figures
- No human exposure data of any kind has been published.
- Pan-receptor agonism means broad tissue effects, which is the main open question in the literature.
- 'Exercise mimetic' is media framing, not a measured clinical endpoint.
Sources and citations
These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.
- [1]Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
Billon C, Sitaula S, Banerjee S, et al. · ACS Chem Biol · 2023 · PMID 36988910
SLU-PP-332 was administered to mice at defined mg/kg doses to demonstrate an ERRα-dependent aerobic exercise response and increased exercise capacity.
View the record - [2]A Synthetic ERR Agonist Alleviates Metabolic Syndrome
Billon C, Schoepke E, Avdagic A, et al. · J Pharmacol Exp Ther · 2023 · PMID 37739806
Mice with diet-induced metabolic syndrome were dosed with SLU-PP-332 to evaluate improvements in metabolic parameters.
View the record
Search the databases yourself
Read the SLU-PP-332 research briefOther metabolic compounds
AdipotidePro-apoptotic peptidomimetic targeting prohibitin in white adipose vasculatureAICARAMP analogue and AMPK activator (small molecule, not a peptide)CagrilintideLong-acting amylin analogue (AMY1 class)GLP1 (semaglutide / Ozempic)GLP-1 receptor agonist
All research protocolsPeptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.